OTCPK:BDUUY (Thailand)
Â
Business Description
Bangkok Dusit Medical Services PCL
NAICS : 622110
Description
Bangkok Dusit Medical Services PCL operates a network of hospitals throughout Thailand under the Bangkok Hospital, Phyathai Hospital, Samitivej Hospital, Paolo Hospital, BNH Hospital, and Royal International Hospital brands. In addition to the firm's core hospital business, it operates a variety of other businesses. The other businesses support the hospital business and include a medical laboratory and manufacture and distribution of medicine and pharmaceutical products. Bangkok Dusit's hospital operations generate the vast majority of its revenue.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.72 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 0.85 | |||||
| Interest Coverage | 25.91 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 8.2 | |||||
| Beneish M-Score | -2.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.9 | |||||
| 3-Year EBITDA Growth Rate | -3 | |||||
| 3-Year EPS without NRI Growth Rate | -5.4 | |||||
| 3-Year FCF Growth Rate | 12 | |||||
| 3-Year Book Growth Rate | 5.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 3.34 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 3.15 | |||||
| 14-Day RSI | 3.37 | |||||
| 6-1 Month Momentum % | -1.24 | |||||
| 12-1 Month Momentum % | 15.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.6 | |||||
| Days Inventory | 12.47 | |||||
| Days Sales Outstanding | 39.49 | |||||
| Days Payable | 28.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 30.5 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.59 | |||||
| Operating Margin % | 18.31 | |||||
| Net Margin % | 13.47 | |||||
| ROE % | 14.27 | |||||
| ROA % | 9.24 | |||||
| ROIC % | 11.82 | |||||
| ROC (Joel Greenblatt) % | 20.15 | |||||
| ROCE % | 14.92 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 39.49 | |||||
| PE Ratio without NRI | 39.49 | |||||
| Shiller PE Ratio | 44.15 | |||||
| Price-to-Owner-Earnings | 44.68 | |||||
| PEG Ratio | 98.73 | |||||
| PS Ratio | 5.34 | |||||
| PB Ratio | 5.59 | |||||
| Price-to-Tangible-Book | 7.18 | |||||
| Price-to-Free-Cash-Flow | 35.55 | |||||
| Price-to-Operating-Cash-Flow | 26.19 | |||||
| EV-to-EBIT | 29.28 | |||||
| EV-to-Forward-EBIT | 29.84 | |||||
| EV-to-EBITDA | 21.48 | |||||
| EV-to-Forward-EBITDA | 21.43 | |||||
| EV-to-Revenue | 5.4 | |||||
| EV-to-Forward-Revenue | 5.12 | |||||
| EV-to-FCF | 35.94 | |||||
| Price-to-Projected-FCF | 3.88 | |||||
| Price-to-Median-PS-Value | 1.06 | |||||
| Price-to-Graham-Number | 3.55 | |||||
| Earnings Yield (Greenblatt) % | 3.42 | |||||
| Forward Rate of Return (Yacktman) % | -0.71 |
